DK1173418T3 - Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid - Google Patents

Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid

Info

Publication number
DK1173418T3
DK1173418T3 DK00926805T DK00926805T DK1173418T3 DK 1173418 T3 DK1173418 T3 DK 1173418T3 DK 00926805 T DK00926805 T DK 00926805T DK 00926805 T DK00926805 T DK 00926805T DK 1173418 T3 DK1173418 T3 DK 1173418T3
Authority
DK
Denmark
Prior art keywords
methoxy
methylaminothiocarbonyl
aminosulfonylphenyl
benzamide
chloro
Prior art date
Application number
DK00926805T
Other languages
English (en)
Inventor
Heinrich Christian Englert
Uwe Gerlach
Harald Schneider
Tobias Metzenthin
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1173418T3 publication Critical patent/DK1173418T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00926805T 1999-04-16 2000-04-04 Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid DK1173418T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19917233A DE19917233A1 (de) 1999-04-16 1999-04-16 Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids

Publications (1)

Publication Number Publication Date
DK1173418T3 true DK1173418T3 (da) 2006-04-10

Family

ID=7904803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00926805T DK1173418T3 (da) 1999-04-16 2000-04-04 Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid

Country Status (33)

Country Link
US (1) US6723751B1 (da)
EP (2) EP1637519B1 (da)
JP (1) JP4662640B2 (da)
KR (1) KR100700302B1 (da)
CN (1) CN1168712C (da)
AR (1) AR023479A1 (da)
AT (2) ATE311364T1 (da)
AU (1) AU773246B2 (da)
BR (1) BR0010658A (da)
CA (1) CA2370388C (da)
CZ (1) CZ302459B6 (da)
DE (3) DE19917233A1 (da)
DK (1) DK1173418T3 (da)
EE (1) EE04612B1 (da)
ES (1) ES2251996T3 (da)
HK (1) HK1046270B (da)
HR (1) HRP20010744B1 (da)
HU (1) HU229082B1 (da)
IL (2) IL145921A0 (da)
ME (1) MEP55708A (da)
MX (1) MXPA01010275A (da)
MY (1) MY122588A (da)
NO (1) NO327798B1 (da)
NZ (1) NZ514788A (da)
PL (1) PL203809B1 (da)
RS (1) RS50916B (da)
RU (1) RU2235089C2 (da)
SI (1) SI1173418T1 (da)
SK (1) SK287175B6 (da)
TR (2) TR200501142T2 (da)
TW (1) TWI276622B (da)
WO (1) WO2000063167A1 (da)
ZA (1) ZA200108400B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080008440A (ko) * 2003-03-17 2008-01-23 니뽄 다바코 산교 가부시키가이샤 Ｃｅｔｐ 억제제의 약제학적 조성물
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0612724T3 (da) * 1993-02-23 1997-06-16 Hoechst Ag Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til deres fremstilling og deres anvendelse som farmaceutika
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1195524C (zh) * 1998-09-10 2005-04-06 阿文蒂斯药物德国有限公司 苯磺酰(硫)脲与β－受体阻滞剂联合在制备用于心脏迷走神经机能障碍治疗和预防的药物中的用途

Also Published As

Publication number Publication date
ATE414059T1 (de) 2008-11-15
EP1637519B1 (en) 2008-11-12
BR0010658A (pt) 2002-02-19
KR100700302B1 (ko) 2007-03-29
NO20015014D0 (no) 2001-10-15
HRP20010744A2 (en) 2003-04-30
CZ20013672A3 (cs) 2002-01-16
NZ514788A (en) 2003-03-28
SK287175B6 (sk) 2010-02-08
CZ302459B6 (cs) 2011-06-01
JP4662640B2 (ja) 2011-03-30
JP2002542230A (ja) 2002-12-10
ZA200108400B (en) 2003-04-30
MEP55708A (en) 2011-05-10
CA2370388C (en) 2009-10-13
MXPA01010275A (es) 2003-07-21
IL145921A (en) 2006-07-05
SI1173418T1 (sl) 2006-02-28
CA2370388A1 (en) 2000-10-26
WO2000063167A1 (en) 2000-10-26
DE19917233A1 (de) 2000-10-19
CN1354744A (zh) 2002-06-19
EP1637519A1 (en) 2006-03-22
HUP0200791A3 (en) 2005-04-28
HU229082B1 (hu) 2013-07-29
NO327798B1 (no) 2009-09-28
KR20010109355A (ko) 2001-12-08
RU2235089C2 (ru) 2004-08-27
HK1046270A1 (en) 2003-01-03
AU4542800A (en) 2000-11-02
TR200501142T2 (tr) 2005-08-22
ATE311364T1 (de) 2005-12-15
YU72001A (sh) 2004-07-15
EE200100532A (et) 2002-12-16
DE60040811D1 (de) 2008-12-24
EP1173418B1 (en) 2005-11-30
RS50916B (sr) 2010-08-31
ES2251996T3 (es) 2006-05-16
EP1173418A1 (en) 2002-01-23
EE04612B1 (et) 2006-04-17
SK14582001A3 (sk) 2002-01-07
IL145921A0 (en) 2002-07-25
DE60024431T2 (de) 2006-07-27
TWI276622B (en) 2007-03-21
NO20015014L (no) 2001-10-15
DE60024431D1 (en) 2006-01-05
AU773246B2 (en) 2004-05-20
PL351245A1 (en) 2003-04-07
CN1168712C (zh) 2004-09-29
MY122588A (en) 2006-04-29
TR200102993T2 (tr) 2002-03-21
US6723751B1 (en) 2004-04-20
HUP0200791A2 (hu) 2002-07-29
AR023479A1 (es) 2002-09-04
HK1046270B (zh) 2005-03-11
PL203809B1 (pl) 2009-11-30
HRP20010744B1 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
IS5989A (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
NO20030550L (no) 17<beta>-karbotioat 17<alfa>-arylkarbonyloksyandrostanderivat som anti-inflammatoriske midler
NL350038I2 (nl) Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DK1140034T3 (da) Formulering af divalproex-natrium med kontrolleret frigivelse
EE200000584A (et) Viirusevastase bensimidasoolühendi kristallilisedvormid
NO20016319L (no) VLA-4 inhibitor-forbindelser
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
HUP0202536A3 (en) Crystals of the sodium salt of pravastatin
NO20013684D0 (no) Substituerte fenetylaminderivater
DK1233960T3 (da) Polymorft salt af anti-migræne lægemiddel
AU5404800A (en) Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate
IS5821A (is) Kristalluð form af ósanetant
DK1173418T3 (da) Krystallinsk form 3 af natriumsaltet af 5-chlor-2-methoxy-N (2- (4-methoxy-3-methylaminothiocarbonyl-aminosulfonylphenyl) ethyl) benzamid
IS6007A (is) Ný morfólínóbensamíðsölt
PT1212095E (pt) Processo para a preparacao de uma formulacao de libertacao retardada
MA26840A1 (fr) Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1
DK0980383T3 (da) Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener
IS5544A (is) Nýtt fosfatsalt af ísóprópýl-metýl-[2-(3-n-própoxýfenoxý)-etýl]amíni
AR027876A4 (es) Juntas para la fijacion de herrajes en cristales
PL344006A1 (en) Α-(1-piperazinyl)acetamido arenecarboxylic acid derivatives as antidiabetic agents